Theriva Biologics leverages FDA and EMA feedback to optimize VCN-01 pivotal trial
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.